Question 1

What is the difference between hepatocellular carcinoma and other liver cancers?

Accepted Answer

Hepatocellular carcinoma (HCC) arises from the main cells of the liver itself and accounts for the large majority of primary liver cancers. Other primary liver cancers, including bile duct cancers that start inside the liver, and rare types like fibrolamellar HCC and angiosarcoma, start from different cell types and are biologically distinct diseases with separate research pathways.

Question 2

Why does underlying liver disease shape liver cancer research?

Accepted Answer

HCC almost always develops in a liver that is already affected by another condition, such as long-standing viral hepatitis, alcohol-related liver disease, or fatty liver disease. The damaged background tissue affects how the liver functions, which in turn affects what treatments can be tolerated. As a result, liver function is a defining concept in HCC research: research designs typically include detailed assessment of liver health, and separate research programs exist for different levels of underlying liver function.

Question 3

What is locoregional treatment in liver cancer?

Accepted Answer

Locoregional treatment refers to therapies delivered directly to the liver tumour, rather than circulating through the whole body like systemic chemotherapy. Examples include treatments that block the blood supply to the tumour, treatments that deliver radiation directly through the blood vessels feeding it, and approaches that destroy the tumour with heat or cold. Combining locoregional treatments with systemic therapies, especially immunotherapy, is one of the most active areas of liver cancer research.

Liver Cancer clinical trials in Australia

Three steps. About 30 seconds.

Describe

Match

Discuss

Liver Cancer clinical trials: common questions

Search other cancer types